The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
Open Access
- 1 December 2010
- journal article
- research article
- Published by Wiley in Chemotherapy Research and Practice
- Vol. 2011, 1-8
Abstract
The major obstacle in platinum chemotherapy is the repair of platinum-damaged DNA that results in increased resistance, reduced apoptosis, and finally treatment failure. Our research goal is to determine and block the mechanisms of platinum resistance. Our recent studies demonstrate that several kinases in the DNA-repair pathway are activated after cells are exposed to cisplatin. These include ATM, p53, and Chk2. The increased Chk2 phosphorylation is modulated by p53 in a wild-type p53 model. Overexpression of p53 by cDNA transfection in wt-p53 (but not p53 deficient) cells doubled the amount of Chk2 phosphorylation 48 hours after cisplatin treatment. p53 knockdown by specific siRNA greatly reduced Chk2 phosphorylation. We conclude that wild-type p53, in response to cisplatin stimulation, plays a role in the upstream regulation of Chk2 phosphorylation at Thr-68. Cells without normal p53 function survive via an alternative pathway in response to the exogenous influence of cisplatin. We strongly suggest that it is very important to include the p53 mutational status in any p53 involved studies due to the functional differentiation of wt p53 and p53 mutant. Inhibition of Chk2 pathway with a Chk2 inhibitor (C3742) increased cisplatin efficacy, especially those with defective p53. Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.Keywords
This publication has 33 references indexed in Scilit:
- Mammalian TIMELESS Is Required for ATM-dependent CHK2 Activation and G2/M Checkpoint ControlJournal of Biological Chemistry, 2010
- Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]The Journal of Pharmacology and Experimental Therapeutics, 2009
- Activated Checkpoint Kinase 2 Provides a Survival Signal for Tumor CellsCancer Research, 2006
- The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastropheOncogene, 2004
- Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage ResponseJournal of Biological Chemistry, 2003
- The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer CellsJournal of Biological Chemistry, 2003
- Checkpoint Kinase 2 (Chk2) Monomers or Dimers Phosphorylate Cdc25C after DNA Damage Regardless of Threonine 68 PhosphorylationJournal of Biological Chemistry, 2002
- Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage‐induced S and G2 checkpoints and enhances apoptotic activity in HEK‐293 cellsFEBS Letters, 2001
- Regulation of p53 in response to DNA damageOncogene, 1999
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994